The Hematology Podcast

Hemoglobinopathies have previously been rare in the Nordic population but with increasing migration we now meet many patients with different types of thalassemias and hemoglobin variants. It is important to recognize these conditions and diagnosis can sometimes be challenging. In this episode  we will meet an expert in hemoglobin disorders who will discuss classification and diagnostic procedures. Britta Landin is associate professor and senior consultant at the Karolinska University Hospital in Stockholm. Host for the podcast is the Swedish hematologist Mats Merup. MAT-DK-2100201(1.0) January 2022

Minimal residual disease (MRD) can today be evaluated in individual patient after treatment using various methods with high sensitivity. MRD indicates remaining malignant cells that could be a source of relapse of the disease. Could MRD also be used as an efficient endpoint in the design of new clinical studies?  With help from Professor Ola Landgren, we will look into the crystal ball and discover what the future may hold for MRD.Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Ola Landgren, Professor of Medicine, Chief of Myeloma Program & Experimental Therapeutics Program. Sylvester Comprehensive Cancer Center, University of MiamiMAT-DK-2100201(1.0) November 2021

Detection of Minimal Residual Disease (MRD) is  becoming more important in different fields of hematology including Multiple Myeloma. Over the past decades we've been able to improve the sensitivity of detecting minimal levels of MRD through innovations in molecular biology. But should MRD always be treated?  Will it give a better outcome for the patient? And do the benefits outweigh the costs?”Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Dr Fredrik Schjesvold, head of the Oslo Myeloma Center.MAT-DK-2100201(1.0) March 2021

One drop of blood, two sheets of glass, 40x objective. Hematological diagnostics demands a keen eye and sound reasoning. At the same time, artificial intelligence is entering the field in a big way. We ask: are the days of Giemsa coloring past us? What will machines be able to do for us, and is there a new role for humans in hematological diagnostics?​ Host for the podcast is the Swedish hematologist Mats Merup. Special guests in this episode are Birgitta Sander, basic researcher and pathologist, senior physician and professor at Karolinska Institute and Morten Goodwin, researcher and professor at the University of Agder in the field of artificial Intelligence.MAT-DK-2100201(1.0) March 2021 

We're currently able to scan the entire human genome in a single day, and the application of genetic sequencing has the potential to improve diagnosis, prognosis and treatment. Ahead lies the opportunity to easily discover rare hematological diseases that might previously have gone unnoticed or would have been hard to diagnose. We look closer at genetic sequencing and discuss its applications.Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Professor Janna Saarela. Jaana is the director of the Norwegian Centre for molecular medicine, and a researcher working to improve our understanding of the disease pathogenesis and mechanisms of human immune disorder. MAT-DK-2100201(1.0) March 2021 

aTTP is a hematological disease so rare that all professionals struggle to identify it. In this episode, we talk to a hematologist who has diagnosed and treated a patient with aTTP, and we discover what actions a hematologist takes, when facing a deadly acute disease which has six incidents per million in a year. ​ Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Henrik Frederiksen, Chief Physician, clinical associate professor, Phd, Department of Haematology X, Odense University Hospital and the Department of Clinical Research, University of Southern Denmark.MAT-DK-2100201(1.0) March 2021 

In The Hematology Podcast, we dig into the clinical, the theoretical, and the practical, as we discuss the past, present, and future of the hematological field.